Brevan Howard Capital Management’s Faeth Therapeutics FTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$261K Buy
+8,787
New +$274K ﹤0.01% 1638
2026
Q2
– Sell
-20,333
Closed -$641K – 2548
2026
Q1
$641K Buy
+20,333
New +$406K 0.01% 1156

Other funds holding FTH

Brevan Howard Capital Management's FTH Position: Q3 2026 in Review

Brevan Howard Capital Management opened a new position in Faeth Therapeutics (FTH) in Q3 2026: 8,787 shares worth $261K. The stake represents ﹤0.01% of the portfolio and ranks #1638 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in FTH as recently as Q1 2026.

Brevan Howard Capital Management first reported a position in FTH in Q1 2026 and has held it in 2 quarters since. The position peaked at $641K in Q1 2026. 78 funds tracked by Wall St. Rank hold FTH as of Q3 2026.

  • Brevan Howard Capital Management held 8,787 shares of Faeth Therapeutics worth $261K as of Q3 2026.
  • Faeth Therapeutics was a new Brevan Howard Capital Management position in Q3 2026.
  • Faeth Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q3 2026, its #1638 holding.
  • Brevan Howard Capital Management first reported a position in Faeth Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Brevan Howard Capital Management's Faeth Therapeutics position peaked at $641K in Q1 2026.
  • 78 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2026.

Based on Brevan Howard Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.